Peptide Comparison
Tirzepatide vs Orforglipron
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Tirzepatide and Orforglipron share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Tirzepatide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Tirzepatide's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Tirzepatide | Orforglipron | |
|---|---|---|
| Class | GIP/GLP-1 dual incretin agonist | Oral non-peptide GLP-1 agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Dual agonism at GIP and GLP-1 receptors; delays gastric emptying; enhances satiety; improves insulin sensitivity [1][2] | Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment [14] |
| Route | SC injection | Oral |
| Half-life | ~5 days | ~29-49 hrs |
| Dosage (research) | 2.5 mg SC weekly (Mounjaro/Zepbound label starting dose, escalate by 2.5 mg monthly to label max 15 mg weekly per SURMOUNT escalation schedule) [1][2][3] | 0.8 mg orally once daily (FOUNDAYO label starting dose, escalate at intervals of at least 30 days through 2.5, 5.5, 9 and 14.5 mg to label max 17.2 mg once daily) [15] |
| Evidence tier | FDA-Approved | FDA-Approved |
| Research depth | 262 indexed | 157 indexed |
| Availability | Prescription | Prescription |
| Reported risks | Nausea; vomiting; diarrhea; pancreatitis risk; gallbladder disease; thyroid C-cell tumor black-box warning [1][2] | GI effects; hepatic enzyme elevations |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Tirzepatide or Orforglipron?
Tirzepatide and Orforglipron share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Tirzepatide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Tirzepatide's evidence base is currently denser.
What is the difference between Tirzepatide and Orforglipron?
Tirzepatide is classed as GIP/GLP-1 dual incretin agonist; Orforglipron is classed as Oral non-peptide GLP-1 agonist. Reported mechanism: Tirzepatide, Dual agonism at GIP and GLP-1 receptors; delays gastric emptying; enhances satiety; improves insulin sensitivity; Orforglipron, Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment. Reported half-life: Tirzepatide, ~5 days; Orforglipron, ~29-49 hrs. Routes in published studies: Tirzepatide, SC injection; Orforglipron, Oral.
Which has stronger evidence, Tirzepatide or Orforglipron?
Tirzepatide and Orforglipron sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tirzepatide is graded FDA-Approved, with 81 cited sources on its reference page and 262 indexed studies. Orforglipron is graded FDA-Approved, with 37 cited sources on its reference page and 157 indexed studies.
Which is more accessible, Tirzepatide or Orforglipron?
Both Tirzepatide and Orforglipron are FDA-approved drugs. Catalog status: Tirzepatide, Prescription; Orforglipron, Prescription.
Are Tirzepatide and Orforglipron ever combined?
Tirzepatide and Orforglipron appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…